Trifas  10 10 mg comprimate 摩尔多瓦 - 罗马尼亚文 - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

trifas 10 10 mg comprimate

menarini international operations luxembourg sa - torasemidum - comprimate - 10 mg

Trifas  20 20 mg/4ml soluţie injectabilă 摩尔多瓦 - 罗马尼亚文 - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

trifas 20 20 mg/4ml soluţie injectabilă

menarini international operations luxembourg sa - torasemidum - soluţie injectabilă - 20 mg/4ml

Trifas  200 200 mg comprimate 摩尔多瓦 - 罗马尼亚文 - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

trifas 200 200 mg comprimate

menarini international operations luxembourg sa - torasemidum - comprimate - 200 mg

Trifas  Cor 5 mg comprimate 摩尔多瓦 - 罗马尼亚文 - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

trifas cor 5 mg comprimate

menarini international operations luxembourg sa - torasemidum - comprimate - 5 mg

Cabometyx 欧盟 - 罗马尼亚文 - EMA (European Medicines Agency)

cabometyx

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - agenți antineoplazici - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.